Branded Legacy Inc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jamie Forrest
- Full Time Employees
- 3
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- 250 National Place Melbourne FL United States of America 32750
- IPO Date
- Jan 3, 2013
- CIK
- 0001794311
- Website
- brandedlegacy.com
- Similar Companies
- Business
- Branded Legacy Inc (OTC: BLEG) is a diversified holding company focused on the development, marketing, and distribution of plant-based functional wellness products and biotechnology solutions targeting addiction treatment and harm reduction. The company offers core products including hemp and cannabinoid-infused beverages, CBD topicals and tinctures, hemp coffees and teas, botanical extracts, alkaloid-based compounds such as mitragynine salt via subsidiary Sycamore BioPharma, and advanced intranasal drug delivery devices through Bio Legacy Evaluative Group for naloxone and other therapeutics; it also provides medicinal ethnobotany products from All In Extracts, LLC. Incorporated in 1981 and headquartered in Melbourne, Florida, Branded Legacy operates primarily in the United States with a GMP-compliant manufacturing facility in Vancouver, British Columbia, Canada, and serves markets across North America, Europe, and the Middle East through strategic client relationships. Recent developments include the July 2025 acquisition of Bio Legacy Evaluative Group (formerly Menlo Health) in an all-stock deal valued at $1.5 million to enter biotech and medical devices; formation of partnerships with Stanford University and McMaster University for addiction research; securing a key client, Monster Group Inc, generating over $70 million annually and projecting over $10 million in company revenue by 2025; closing the acquisition of All In Extracts LLC in January 2024; submission of a provisional patent in September 2025 for its air-driven intranasal delivery device; initiation of unitary device mold development in October 2025; retirement of over 842 million common shares; expansion via MycoEnlighten letter of intent and Marij Pharmaceuticals acquisition; relocation to a state-of-the-art biotech facility; and a 1,000% revenue increase through subsidiary additions. These initiatives position Branded Legacy to capture growth in the naloxone market, projected to exceed $1.16 billion by 2032, alongside vaccine and cold-chain medication delivery innovations.
Branded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of Shares
Branded Legacy, Inc. Announces Complete Management Overhaul and Strategic Reset Under New Leadership
Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development
Branded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone Development
Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver
Branded Legacy, Inc. Forms Strategic Partnership with Stanford University's Dr. Eran Bendavid to Advance Addiction Solutions
Branded Legacy, Inc. Partners with McMaster University: Revolutionizing Addiction Treatment Through Cutting-Edge Clinical Research and Regulatory Pathways
Branded Legacy, Inc. Finalizes Transformative Acquisition of Bio Legacy Evaluative Group (f/k/a Menlo Health), Unlocking Explosive Growth Potential in Biotech and Drug Delivery
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue
Branded Legacy, Inc. Secures Key Client with $70,000,000 Annual Revenue; Expects to Surpass $10,000,000 in 2025
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million
Branded Legacy, Inc. To Add $320,000 In Revenue With New White Label Contract
Branded Legacy, Inc Announces White Label Deal with Kava & Hobbs, LLC for Kava Vape formulation
Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.
Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC
Branded Legacy, Inc. Expands Operations with Move to State of the Art Biotech Facility in Melbourne, FL